Publications by authors named "A Broniscer"

Background: The term gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features could not be established.

Methods: We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization.

Results: Median overall survival (OS) was 15.

View Article and Find Full Text PDF
Article Synopsis
  • High-grade gliomas (HGG) in young children are complex and have unpredictable outcomes, necessitating further study beyond retrospective analyses.
  • A study conducted at St. Jude Children’s Research Hospital analyzed a cohort of children with histologically confirmed HGG using advanced genomic profiling and imaging, leading to insights into four distinct tumor categories.
  • The findings revealed that infant-type hemispheric gliomas (IHG) are the most common, especially in very young children, with significantly better survival rates compared to other types of HGG, suggesting a need for tailored therapeutic approaches.
View Article and Find Full Text PDF

How abnormal neurodevelopment relates to the tumour aggressiveness of medulloblastoma (MB), the most common type of embryonal tumour, remains elusive. Here we uncover a neurodevelopmental epigenomic programme that is hijacked to induce MB metastatic dissemination. Unsupervised analyses of integrated publicly available datasets with our newly generated data reveal that SMARCD3 (also known as BAF60C) regulates Disabled 1 (DAB1)-mediated Reelin signalling in Purkinje cell migration and MB metastasis by orchestrating cis-regulatory elements at the DAB1 locus.

View Article and Find Full Text PDF

Methylation profiling has radically transformed our understanding of tumors previously called central nervous system primitive neuro-ectodermal tumors (CNS-PNET). While this marks a momentous step toward defining key differences, reclassification has thrown treatment into disarray. To shed light on response to therapy and guide clinical decision-making, we report outcomes and molecular features of children with CNS-PNETs from two multi-center risk-adapted studies (SJMB03 for patients ≥ 3 years; SJYC07 for patients < 3 years) complemented by a non-protocol institutional cohort.

View Article and Find Full Text PDF